What Probiotics Have Been Studied For Their Effects On Digestive Health?
Quick answer
Certain probiotic strains such as Bacillus coagulans, Bifidobacterium animalis subsp. lactis BB-12, Escherichia coli Nissle 1917, and multispecies probiotic mixtures have shown evidence of helping with digestive problems, particularly in functional dyspepsia and irritable bowel syndrome (IBS).
🔬 What the research shows
High-quality randomized controlled trials support the use of Bacillus coagulans MY01 and Bacillus subtilis MY02 for functional dyspepsia, showing improved symptoms and safety. For IBS, multispecies probiotics including Bifidobacterium animalis subsp. lactis BB-12, Lactobacillus rhamnosus GG, and others have demonstrated symptom relief and microbiota stabilization. Escherichia coli Nissle 1917 showed benefits mainly in IBS patients with prior gastroenteritis or antibiotic use. Lactobacillus casei GG showed no significant overall benefit but may help diarrhea-predominant IBS. Lactiplantibacillus plantarum 299v did not show significant efficacy in IBS. Some probiotic mixtures containing Lactobacillus rhamnosus GG and others also showed symptom improvement in IBS. Evidence for probiotics in dyspepsia related to Helicobacter pylori is low and mainly theoretical. Safety profiles across studies were generally good with no significant adverse events. Limitations include small sample sizes in some studies, heterogeneity of probiotic strains and IBS subtypes, and the need for more large-scale, blinded trials.
Best studied probiotic strains
Bacillus coagulans MY01 and Bacillus subtilis MY02
High-quality RCT (PMID 34358486) showed these spore-forming probiotics improved symptoms in functional dyspepsia with a higher responder rate than placebo and good safety.
Effective in functional dyspepsia; may modulate immune and microbial factors.
Bifidobacterium animalis subsp. lactis BB-12 (part of multispecies probiotic)
High-quality RCT (PMID 17919270) showed multispecies probiotic including BB-12 reduced IBS symptoms, especially abdominal pain and distension, and stabilized intestinal microbiota.
Used in combination with other strains; benefits IBS symptoms.
Escherichia coli Nissle 1917
High-quality RCT (PMID 22130826) showed significant symptom improvement in IBS patients, particularly those with prior gastroenteritis or antibiotic use.
May be more effective in IBS subgroups with altered gut flora.
Lactobacillus rhamnosus GG (part of probiotic mixtures)
High-quality RCTs (PMID 16128676, 17919270) showed probiotic mixtures containing L. rhamnosus GG alleviated IBS symptoms including abdominal pain and bloating.
Often used in combination with other strains; benefits IBS symptoms.
👥 Who may benefit
✅ Safety
Probiotics studied were generally safe and well tolerated with adverse event rates similar to placebo. Serious adverse events were rare and unlikely related to probiotic use.
⚠️ Limitations
Some studies had small sample sizes or open-label designs. Effects may vary by probiotic strain and patient subgroup. More large-scale, double-blind, placebo-controlled trials are needed to confirm findings and clarify optimal strains and doses. Evidence for probiotics in Helicobacter pylori-associated dyspepsia is limited and mostly theoretical.